M2 PHARMA-October 20, 2017-Nexus Pharmaceuticals reports launch of US FDA approved Procainamide HCL Injection, USP
Nexus Pharmaceuticals disclosed on Thursday the availability of Procainamide HCL Injection, USP in a multi dose vial containing 1,000 mg per 2 mL (500 mg/mL) or as a multi dose vial containing 1,000 mg per 10 ml (100 mg/ml) in the US with immediate effect.